- $5.46bn
- $4.72bn
- $4.04m
Annual income statement for CG Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.4 | 0.191 | 0.204 | 1.14 | 4.04 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | -0.607 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 23 | 35.4 | 55.7 | 116 | 195 |
| Operating Profit | -12.6 | -35.2 | -55.4 | -115 | -191 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -12.8 | -35.4 | -48.6 | -88 | -161 |
| Net Income After Taxes | -12.8 | -35.4 | -48.6 | -88 | -161 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -12.8 | -35.4 | -48.6 | -88 | -161 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18.4 | -43.8 | -67.8 | -88 | -161 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.29 | -0.69 | -1.07 | -1.41 | -2.08 |
| Dividends per Share |